The Journal

Field note · 4 min read

What 18,000 panels taught us about Lp(a).

By Shantivita Data · May 14, 2027

Almost no one talks about Lp(a) until they have to. We looked at every Long Arc Panel run in 2026 and found a familiar shape: a marker we ignore because we can't change it.

Lipoprotein(a) is a tightly genetic risk factor for cardiovascular disease. It runs in families. Diet barely moves it. Exercise barely moves it. There is no approved drug today that lowers it meaningfully — though several are in late-stage trials.

About one in five adults has an elevated Lp(a). Most of them have never heard of it.

What our data shows

In our cohort of 18,200 panels run in 2026, 21% had Lp(a) above the 75 nmol/L threshold our medical board considers high-risk. Almost none of those members had been told.

Of the elevated subset, members who knew it was elevated showed a different pattern at re-test: tighter ApoB management (40% lower median), more sleep adherence, more Zone 2. They worked the levers they had, because they knew which lever was locked.

The takeaway

Knowing your Lp(a) does not reduce your Lp(a). It does change how aggressively you manage every other lever that is yours to move. That alone is worth measuring, once, in your life.